Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study

This study has been completed.

First Received: September 27, 2005 Last Updated: June 10, 2009 History of Changes

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00228514

Purpose

At one site, patients participating in the Corona main study are asked to participate in the PET-substudy. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed to study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve)

Condition	Intervention	Phase
Rosuvastatin Heart Failure Positron Emission Tomography (PET)	Drug: Rosuvastatin Procedure: Positron emission tomography	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) PET Sub Study

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure Nuclear Scans

Drug Information available for: Rosuvastatin calcium Rosuvastatin

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

To study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve). Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed.

Secondary Outcome Measures:

To study the effect of rosuvastatin in Chronic Heart Failure on mismatch. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed.

Estimated Enrollment:	40
Study Start Date:	February 2004
Study Completion Date:	July 2007

Eligibility

Ages Eligible for Study:	60 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients fulfilling the in and exclusion criteria of the CORONA study and separate informed consent for participation in the sub study.

Exclusion Criteria:

See above

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00228514

Locations

Netherlands
Research Site
Groningen, Netherlands

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

AstraZeneca CV Medical Department

AstraZeneca BV

More Information

No publications provided

Study ID Numbers:	4522IL/0098 Dutch SubStudy, D3562C00098
Study First Received:	September 27, 2005
Last Updated:	June 10, 2009
ClinicalTrials.gov Identifier:	NCT00228514 History of Changes
Health Authority:	Netherlands: Medical Ethics Review Committee (METC)

Study placed in the following topic categories:

Antimetabolites
Heart Failure
Rosuvastatin
Heart Diseases

Antilipemic Agents
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Additional relevant MeSH terms:

Antimetabolites
Heart Failure
Rosuvastatin
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses

Antilipemic Agents
Enzyme Inhibitors
Cardiovascular Diseases
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 03, 2009